Search research articles
Contact Us
Filters
Showing results (101-110 of 143) with videos related to
Page
of 15
Sort By:
Blood
|
April 7, 2021
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al.
Blood Advances
|
March 19, 2024
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis
Julia Driessen, Fer de Wit, Alex F Herrera, et al.
Blood
|
July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
David J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
British Journal of Haematology
|
January 21, 2010
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
Craig H Moskowitz, Joachim Yahalom, Andrew D Zelenetz, et al.
Blood Advances
|
January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
Erel Joffe, Yan Leyfman, Esther Drill, et al.
Blood
|
February 2, 2018
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
Craig S Sauter, Matthew J Matasar, Heiko Schoder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma
Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2010
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
Craig H Moskowitz, Heiko Schöder, Julie Teruya-Feldstein, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 8, 2018
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group
Andrea K Ng, Joachim Yahalom, Jayant S Goda, et al.
Blood
|
June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 143) with videos related to
Sort By:
Page
of 15
Blood
|
April 7, 2021
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al.
Blood Advances
|
March 19, 2024
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis
Julia Driessen, Fer de Wit, Alex F Herrera, et al.
Blood
|
July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
David J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
British Journal of Haematology
|
January 21, 2010
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
Craig H Moskowitz, Joachim Yahalom, Andrew D Zelenetz, et al.
Blood Advances
|
January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
Erel Joffe, Yan Leyfman, Esther Drill, et al.
Blood
|
February 2, 2018
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
Craig S Sauter, Matthew J Matasar, Heiko Schoder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma
Christian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2010
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
Craig H Moskowitz, Heiko Schöder, Julie Teruya-Feldstein, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 8, 2018
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group
Andrea K Ng, Joachim Yahalom, Jayant S Goda, et al.
Blood
|
June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Page
of 15